Pacific Biosciences of California Inc

11. Nov. 2026, 23:01 UTC

Pacific Biosciences of California, Inc. is trading higher in after-market hours, maintaining a cumulative return since Wednesday's close amid a broader market rise.

10. Nov. 2026, 22:01 UTC

Pacific Biosciences announces a sales agreement with Allen & Co. for up to $100 million in common stock through an at-the-market equity offering program.

9. Nov. 2026, 21:03 UTC

Pacific Biosciences is advancing sharply, reaching its highest cumulative return since Friday, despite initial volatility earlier in the session.

7. Nov. 2026, 00:01 UTC

Pacific Biosciences of California, Inc. shares are trading modestly lower in after-market hours, continuing a trend of lower closes over the past three sessions.

6. Nov. 2026, 23:41 UTC

Pacific Biosciences of California, Inc. is trading modestly lower in after-market hours, marking its fourth consecutive session of declines.

5. Nov. 2026, 23:36 UTC

ARK Genomic Revolution ETF declined in after-market trading as several holdings reported larger-than-expected net losses, with Pacific Biosciences also falling modestly.

4. Nov. 2026, 23:31 UTC

Pacific Biosciences reports Q3 revenue of $40.6 million, exceeding expectations, and narrows 2026 revenue guidance to $155 million to $160 million.

3. Nov. 2026, 23:41 UTC

Pacific Biosciences is advancing in after-market trading, supported by positive economic indicators and a broadly higher market, despite mixed earnings from Apple.

2. Nov. 2026, 23:11 UTC

Pacific Biosciences of California, Inc. is seeing notable strength in after-market trading, recovering from a low point shortly after the market closed.

31. Okt. 2026, 00:01 UTC

In after-market trading, Pacific Biosciences of California, Inc. has advanced sharply since Friday's close, remaining well above its 20-day moving average.

30. Okt. 2026, 23:41 UTC

Pacific Biosciences is advancing in after-market trading, reaching a high that significantly exceeds Friday's close and is well above its 20-day moving average.

29. Okt. 2026, 23:01 UTC

Pacific Biosciences of California, Inc. is trading lower in after-market hours, reflecting a broader market decline influenced by disappointing earnings from Illumina.

28. Okt. 2026, 23:02 UTC

Pacific Biosciences of California, Inc. is trading lower in after-market hours, reflecting the broader market's decline following the Fed's interest rate decision.

27. Okt. 2026, 23:06 UTC

Pacific Biosciences of California, Inc. is trading modestly lower in after-market hours, continuing a downward trend despite strong performance over the past month.

26. Okt. 2026, 23:06 UTC

Pacific Biosciences of California Inc is trading lower in after-market hours, retracing from an earlier gain, despite a strong one-month performance.

23. Okt. 2026, 19:16 UTC

Pacific Biosciences of California Inc is trading roughly flat, showing little change since Thursday's close, while remaining below its 20-day moving average.

22. Okt. 2026, 19:56 UTC

Pacific Biosciences of California Inc shares fell, influenced by declines in the ARK Genomic Revolution ETF and its holdings, including 10X Genomics and Illumina.

21. Okt. 2026, 23:16 UTC

Pacific Biosciences of California Inc is trading modestly higher in after-market hours, marking its fifth consecutive session of gains.

20. Okt. 2026, 23:16 UTC

Pacific Biosciences of California Inc is trading modestly higher in after-market hours following Tuesday's close, amid ongoing volatility within its one-month trading range.

19. Okt. 2026, 20:07 UTC

Pacific Biosciences announces a multi-year collaboration with Verily Health to integrate HiFi sequencing technology with Verily's AI platform for clinico-genomic datasets.

16. Okt. 2026, 23:06 UTC

Pacific Biosciences of California Inc is effectively unchanged in after-market trading, having retraced from earlier highs amid recent declines below its 20-day moving average.

15. Okt. 2026, 23:02 UTC

After-market hours, the ARK Genomic Revolution ETF (ARKG) is trading higher, supported by a Neutral rating for CRISPR Therapeutics from UBS and gains in key holdings.

14. Okt. 2026, 23:21 UTC

Pacific Biosciences shares declined in after-market trading, marking the fourth consecutive session of lower prices, reaching a recent low shortly before the latest timestamp.

13. Okt. 2026, 23:06 UTC

Pacific Biosciences of California Inc's shares were roughly flat in after-market trading, following three consecutive lower daily closes while remaining above the 20-day moving average.

12. Okt. 2026, 22:16 UTC

Pacific Biosciences of California Inc is trading roughly flat in after-market hours, with the stock positioned around the middle of its one-month range.

9. Okt. 2026, 20:07 UTC

UBS initiated coverage of Pacific Biosciences with a Neutral rating and a price target of $1.35, adjusting its Fair Value estimate to $2.40 per share.

8. Okt. 2026, 23:20 UTC

Pacific Biosciences shares declined significantly in after-market trading, reversing earlier gains and marking a notable drop compared to Thursday's close.

7. Okt. 2026, 23:06 UTC

Pacific Biosciences of California Inc declined during after-market hours on Wednesday, retracing significantly from its prior close despite strong recent performance.

6. Okt. 2026, 23:06 UTC

Pacific Biosciences of California Inc declined in after-market trading, moving lower since Tuesday's close, despite strong performance over the past month.

5. Okt. 2026, 20:03 UTC

Pacific Biosciences of California Inc is higher in Monday's trading, continuing its upward trend since Friday, despite earlier pulling back from a session high.